Kate Therapeutics
Nathan Jones is an experienced professional who currently holds the position of Senior Vice President at Kate Therapeutics. Prior to this role, Nathan held Vice President positions at Passage Bio and Exonics Therapeutics. Nathan also has a background in gene therapy development, having worked at Sanofi as the Director of Gene Therapy Development and Sr Scientist. Nathan holds a PhD from Purdue University and a BS from The University of Kansas.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.